A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan

BackgroundAnti-programmed death-1 (PD-1) antibodies are the mainstay for the treatment of unresectable or high-risk melanoma. However, real-world data on the safety profile of their extended-interval doses (EDs) are limited, particularly in Asian patients with melanoma.Materials and methodsIn this s...

Full description

Bibliographic Details
Main Authors:	Takamichi Ito, Yumiko Kaku-Ito, Fumitaka Ohno, Takeshi Nakahara
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Series:	Frontiers in Medicine
Subjects:	acral melanoma Asian population nivolumab PD-1 pembrolizumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1293397/full

Similar Items

Nail Apparatus Melanoma: Current Management and Future Perspectives
by: Takamichi Ito, et al.
Published: (2023-03-01)

Narrow-Margin Excision for Invasive Acral Melanoma: Is It Acceptable?
by: Takamichi Ito, et al.
Published: (2020-07-01)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
by: Lu Si, et al.
Published: (2022-10-01)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)

Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy
by: Anna Lorenz, et al.
Published: (2022-10-01)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Differences in the Clinical and Molecular Profiles of Subungual Melanoma and Acral Melanoma in Asian Patients
by: So-Young Ahn, et al.
Published: (2023-09-01)

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
by: Thilo Gambichler, et al.
Published: (2019-12-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
by: Paweł Rogala, et al.
Published: (2022-04-01)

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma
by: Yasuhiro Fujisawa, et al.
Published: (2019-05-01)

Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
by: Pawel Teterycz, et al.
Published: (2020-10-01)

Acral Lentiginous Melanoma in Situ: A Diagnostic and Management Challenge
by: Hyun Sun Park, et al.
Published: (2010-04-01)

Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma
by: Steven H. Sun, et al.
Published: (2021-10-01)

Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients
by: Philippe Saiag, et al.
Published: (2022-08-01)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
by: Selina K. Wong, et al.
Published: (2021-11-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors
by: Kremena Petrova Trichkova, et al.
Published: (2024-01-01)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
by: Melissa Bersanelli, et al.
Published: (2022-05-01)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
by: Matthew D Biniakewitz, et al.
Published: (2021-01-01)

Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases
by: Yusuke Muto, et al.
Published: (2022-08-01)

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
by: Ernesto Rossi, et al.
Published: (2019-07-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
by: Dai Ogata, et al.
Published: (2021-04-01)

Acral lentiginous melanoma
by: Sachin A Badge, et al.
Published: (2015-01-01)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
by: Leanne Perez, et al.
Published: (2022-05-01)

TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway
by: Chi-Che Hsieh, et al.
Published: (2023-01-01)

Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
by: Marie‐Alix Mangin, et al.
Published: (2021-05-01)

Preoperative Screening CT and PET/CT Scanning for Acral Melanoma: Is it Necessary?
by: Taketoshi Ide, et al.
Published: (2021-02-01)

Management of acral lentiginous melanoma: current updates and future directions
by: Michelle M. Dugan, et al.
Published: (2024-02-01)

Acral lentiginous melanoma in situ with a characteristically benign dermatoscopic parallel-furrow pattern
by: Shifa Akhtar, BS, et al.
Published: (2022-04-01)

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
by: Kartik Sehgal, et al.
Published: (2020-06-01)

Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
by: Daniella Kuzmanovszki, et al.
Published: (2022-07-01)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by: Carl Morrison, et al.
Published: (2018-05-01)

News in immunotherapy for metastatic melanoma: prolgolimab in clinical practice (authors' experience)
by: Liana V. Oganesyan, et al.
Published: (2023-12-01)

Melanoma en pacientes receptores de un trasplante de órgano sólido
by: C. González-Cruz, et al.
Published: (2021-03-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

First-line treatment of metastatic melanoma: role of nivolumab
by: Force J, et al.
Published: (2017-02-01)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
by: Kyoichi Kaira, et al.
Published: (2021-03-01)